▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : 640900330
▶ Storage : Airtight container, room temperature (1~30℃)
Yellow-brown oval film-coated tablet
Simvastatin 20mg
1. Reduced risk of cardiovascular disease
Adults patients with high risk of coronary heart disease incidents due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke or other cerebrovascular disease
Recommended initial dose is 40mg per day Simvastatin.
2. Hyperlipidemia
1) Reduced risk in hypercholesterolemia patients with coronary heart disease
The recommended initial dose for this drug is 20mg, administered in the evening once a day. Mild to moderately severe hypercholesterolemia patients may be started on 10mg of this drug. Administration of 5 to 40mg of this drug in the evening once a day is recommended.
Dose should be appropriately adjusted depending on initial LDL-C levels prior to administration, target level of therapy, and patient response to the drug. Measure at 4 weeks after cholesterol therapy is begun and at regular intervals thereafter, adjusting administration dose accordingly. Reduce dose when cholesterol level is reduced to or below the target level.
1. Reduced risk for the following cardiovascular diseases
In adult patients with high risk of coronary artery incidents due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke or other cerebrovascular disease:
1) Reduced risk of death from coronary heart disease
2) Reduced risk of nonfatal myocardial infarction and stroke
3) Reduced risk from coronary and non-coronary angioplasty
2. Hyperlipidemia
1) Supplement to dietary therapy to lower elevated Total-C, LDL-C, Apo-B protein, and triglyceride levels and increase HDL-C levels in patients of primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson Type IIa and IIb)
2) Type III : Primary abetalipoproteinemia
3) Type IV : Hypertriglyceridemia
4) Concomitant use with other lipid-lowering drugs (e.g. LDL-apheresis) to lower Total-C and LDL-C levels in homozygous familial hypercholesterolemia patients, or use when treatment using other lipid-lowering drugs is not possible.
Before beginning treatment with this drug, check for causes of subsequent hyperlipidemia and measure lipid concentrations, such as Total-C, HDL-C and triglycerides.Yellow-brown oval film-coated tablet
Simvastatin 20mg
1. Reduced risk of cardiovascular disease
Adults patients with high risk of coronary heart disease incidents due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke or other cerebrovascular disease
Recommended initial dose is 40mg per day Simvastatin.
2. Hyperlipidemia
1) Reduced risk in hypercholesterolemia patients with coronary heart disease
The recommended initial dose for this drug is 20mg, administered in the evening once a day. Mild to moderately severe hypercholesterolemia patients may be started on 10mg of this drug. Administration of 5 to 40mg of this drug in the evening once a day is recommended.
Dose should be appropriately adjusted depending on initial LDL-C levels prior to administration, target level of therapy, and patient response to the drug. Measure at 4 weeks after cholesterol therapy is begun and at regular intervals thereafter, adjusting administration dose accordingly. Reduce dose when cholesterol level is reduced to or below the target level.
1. Reduced risk for the following cardiovascular diseases
In adult patients with high risk of coronary artery incidents due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke or other cerebrovascular disease:
1) Reduced risk of death from coronary heart disease
2) Reduced risk of nonfatal myocardial infarction and stroke
3) Reduced risk from coronary and non-coronary angioplasty
2. Hyperlipidemia
1) Supplement to dietary therapy to lower elevated Total-C, LDL-C, Apo-B protein, and triglyceride levels and increase HDL-C levels in patients of primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson Type IIa and IIb)
2) Type III : Primary abetalipoproteinemia
3) Type IV : Hypertriglyceridemia
4) Concomitant use with other lipid-lowering drugs (e.g. LDL-apheresis) to lower Total-C and LDL-C levels in homozygous familial hypercholesterolemia patients, or use when treatment using other lipid-lowering drugs is not possible.
Before beginning treatment with this drug, check for causes of subsequent hyperlipidemia and measure lipid concentrations, such as Total-C, HDL-C and triglycerides.
